表紙
市場調查報告書

戒煙·戒尼古丁成癮的全球市場:2020年∼2024年

Global Smoking Cessation and Nicotine De-addiction Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 926225
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
戒煙·戒尼古丁成癮的全球市場:2020年∼2024年 Global Smoking Cessation and Nicotine De-addiction Market 2020-2024
出版日期: 2020年03月03日內容資訊: 英文 120 Pages
簡介

全球戒煙·戒尼古丁成癮市場在2020年∼2024年的預測期間內,預計將以13%的年複合成長率增長,並達到166億美元的規模。該市場成長主要因素有創新產品以及越來越多的人嘗試戒菸。

本報告提供全球戒煙·戒尼古丁成癮市場相關調查分析,提供市場規模及成長率,市場趨勢,推動市場要素,課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

摘要整理

  • 市場概況

市場形勢

  • 市場生態系統
  • 價值鏈分析

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模:2019年
  • 市場預測:2019-2024年的預測

波特的五力分析

  • 波特的五力分析摘要
  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 對手的威脅
  • 市場情況

市場區隔:各產品

  • 市場區隔
  • 各產品比較:市場規模與預測2019-2024
  • 電子香煙
  • NRT(尼古丁替代療法)
  • 藥物療法
  • 市場機會:各產品

客戶形勢

  • 概要

各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模與預測2019-2024
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲地區
  • 主要國家
  • 市場機會:各地區

成長要素,課題,及趨勢

  • 市場成長要素
  • 交易量的成長要素-需求主導型成長
  • 交易量的成長要素-供給主導型成長
  • 交易量的成長要素-外部要素
  • 交易量的成長要素-需求轉移到鄰近市場
  • 價格上升要素-通貨膨脹
  • 價格成長要素-從低價格單位轉變到高價格單位
  • 市場課題
  • 市場趨勢

業者情勢

  • 概要
  • 業者情勢
  • 形勢的創新

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • British American Tobacco Plc
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Imperial Brands Plc
  • 日本煙草產業
  • Johnson&Johnson Services Inc.
  • JUUL Labs Inc.
  • Pfizer Inc.
  • Philip Morris International Inc.

附錄

  • 調查範圍
  • 美金的貨幣換算比率
  • 調查方法
  • 簡稱的清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR40398

Technavio has been monitoring the global smoking cessation and nicotine de-addiction market 2020-2024 and it is poised to grow by USD 16.6 bn during 2020-2024, progressing at a CAGR of 13% during the forecast period. Our reports on global smoking cessation and nicotine de-addiction market 2020-2024 provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing number of people trying to quit smoking. In addition, product innovations is anticipated to boost the growth of the global smoking cessation and nicotine de-addiction market 2020-2024 as well.

Market Segmentation

Technavio's ‘ global smoking cessation and nicotine de-addiction market 2020-2024’ is segmented as below:

Product:

  • E-cigarette
  • NRT
  • Drug Therapy

Geographic segmentation

  • APAC
  • Europe
  • MEA
  • North America
  • South America

Key Trends for global smoking cessation and nicotine de-addiction market 2020-2024 growth

This study identifies product innovations as the prime reasons driving the global smoking cessation and nicotine de-addiction market 2020-2024 growth during the next few years.

Prominent vendors in global smoking cessation and nicotine de-addiction market 2020-2024

We provide a detailed analysis of around 25 vendors operating in the global smoking cessation and nicotine de-addiction market 2020-2024, including some of the vendors such as British American Tobacco Plc, Cipla Ltd., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline Plc, Imperial Brands Plc, Japan Tobacco Inc., Johnson & Johnson Services Inc., JUUL Labs Inc., Pfizer Inc. and Philip Morris International Inc. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product placement
  • E-cigarette - Market size and forecast 2019-2024
  • NRT - Market size and forecast 2019-2024
  • Drug therapy - Market size and forecast 2019-2024
  • Market opportunity by Product

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • South America - Market size and forecast 2019-2024
  • MEA - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher-priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • British American Tobacco Plc
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Imperial Brands Plc
  • Japan Tobacco, Inc.
  • Johnson & Johnson Services Inc.
  • JUUL Labs, Inc.
  • Pfizer Inc.
  • Philip Morris International Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits:

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 4
  • 5.Key Finding 5
  • 6.Key Finding 6
  • 7.Key Finding 7
  • 8.Market in focus
  • 9.Parent market
  • 10.Market characteristics
  • 11.Product / Service portfolio of key vendors included in the market definition
  • 12.Market segments
  • 13.Global - Market size and forecast 2019 - 2024 ($ billion)
  • 14.Global market: Year-over-year growth 2019 - 2024 (%)
  • 15.Five forces analysis 2019 & 2024
  • 16.Bargaining power of buyers
  • 17.Bargaining power of suppliers
  • 18.Threat of new entrants
  • 19.Threat of substitutes
  • 20.Threat of rivalry
  • 21.Market condition - Five forces 2019
  • 22.Product placement - Market share 2019-2024 (%)
  • 23.Comparison by Product placement
  • 24.E-cigarette - Market size and forecast 2019-2024 ($ billion)
  • 25.E-cigarette - Year-over-year growth 2019-2024 (%)
  • 26.NRT - Market size and forecast 2019-2024 ($ billion)
  • 27.NRT - Year-over-year growth 2019-2024 (%)
  • 28.Drug therapy - Market size and forecast 2019-2024 ($ billion)
  • 29.Drug therapy - Year-over-year growth 2019-2024 (%)
  • 30. Market opportunity by Product
  • 31.Customer landscape
  • 32.Market share by geography 2019-2024 (%)
  • 33.Geographic comparison
  • 34.North America - Market size and forecast 2019-2024 ($ billion)
  • 35.North America - Year-over-year growth 2019-2024 (%)
  • 36.Europe - Market size and forecast 2019-2024 ($ billion)
  • 37.Europe - Year-over-year growth 2019-2024 (%)
  • 38.APAC - Market size and forecast 2019-2024 ($ billion)
  • 39.APAC - Year-over-year growth 2019-2024 (%)
  • 40.South America - Market size and forecast 2019-2024 ($ billion)
  • 41.South America - Year-over-year growth 2019-2024 (%)
  • 42.MEA - Market size and forecast 2019-2024 ($ billion)
  • 43.MEA - Year-over-year growth 2019-2024 (%)
  • 44.Key leading countries
  • 45.Market opportunity by geography ($ billion)
  • 46.Impact of drivers
  • 47.Impact of challenges
  • 48.Landscape disruption
  • 49.Industry risks
  • 50.Vendors covered
  • 51.Market positioning of vendors
  • 52.British American Tobacco Plc - Overview (1/3)
  • 53.British American Tobacco Plc - Overview (2/3)
  • 54.British American Tobacco Plc - Overview (3/3)
  • 55.British American Tobacco Plc - Product and service
  • 56.British American Tobacco Plc - Key offerings
  • 57.British American Tobacco Plc - Key customers
  • 58.British American Tobacco Plc - Segment focus
  • 59.Cipla Ltd. - Overview (1/3)
  • 60.Cipla Ltd. - Overview (2/3)
  • 61.Cipla Ltd. - Overview (3/3)
  • 62.Cipla Ltd. - Business segments
  • 63.Cipla Ltd. - Key offerings
  • 64.Cipla Ltd. - Key customers
  • 65.Cipla Ltd. - Segment focus
  • 66.Dr. Reddy's Laboratories Ltd. - Overview (1/3)
  • 67.Dr. Reddy's Laboratories Ltd. - Overview (2/3)
  • 68.Dr. Reddy's Laboratories Ltd. - Overview (3/3)
  • 69.Dr. Reddy's Laboratories Ltd. - Business segments
  • 70.Dr. Reddy's Laboratories Ltd. - Key offerings
  • 71.Dr. Reddy's Laboratories Ltd. - Key customers
  • 72.Dr. Reddy's Laboratories Ltd. - Segment focus
  • 73.GlaxoSmithKline Plc - Overview (1/3)
  • 74.GlaxoSmithKline Plc - Overview (2/3)
  • 75.GlaxoSmithKline Plc - Overview (3/3)
  • 76.GlaxoSmithKline Plc - Business segments
  • 77.GlaxoSmithKline Plc - Key offerings
  • 78.GlaxoSmithKline Plc - Key customers
  • 79.GlaxoSmithKline Plc - Segment focus
  • 80.Imperial Brands Plc - Overview (1/3)
  • 81.Imperial Brands Plc - Overview (2/3)
  • 82.Imperial Brands Plc - Overview (3/3)
  • 83.Imperial Brands Plc - Business segments
  • 84.Imperial Brands Plc - Key offerings
  • 85.Imperial Brands Plc - Key customers
  • 86.Imperial Brands Plc - Segment focus
  • 87.Japan Tobacco Inc. - Overview (1/3)
  • 88.Japan Tobacco Inc. - Overview (2/3)
  • 89.Japan Tobacco Inc. - Overview (3/3)
  • 90.Japan Tobacco Inc. - Business segments
  • 91.Japan Tobacco Inc. - Key offerings
  • 92.Japan Tobacco Inc. - Key customers
  • 93.Japan Tobacco Inc. - Segment focus
  • 94.Johnson & Johnson Services Inc. - Overview (1/3)
  • 95.Johnson & Johnson Services Inc. - Overview (2/3)
  • 96.Johnson & Johnson Services Inc. - Overview (3/3)
  • 97.Johnson & Johnson Services Inc. - Business segments
  • 98.Johnson & Johnson Services Inc. - Key offerings
  • 99.Johnson & Johnson Services Inc. - Key customers
  • 100.Johnson & Johnson Services Inc. - Segment focus
  • 101.JUUL Labs Inc. - Overview (1/3)
  • 102.JUUL Labs Inc. - Overview (2/3)
  • 103.JUUL Labs Inc. - Overview (3/3)
  • 104.JUUL Labs Inc. - Product and service
  • 105.JUUL Labs Inc. - Key offerings
  • 106.JUUL Labs Inc. - Key customers
  • 107.JUUL Labs Inc. - Segment focus
  • 108.Pfizer Inc. - Overview (1/3)
  • 109.Pfizer Inc. - Overview (2/3)
  • 110.Pfizer Inc. - Overview (3/3)
  • 111.Pfizer Inc. - Business segments
  • 112.Pfizer Inc. - Key offerings
  • 113.Pfizer Inc. - Key customers
  • 114.Pfizer Inc. - Segment focus
  • 115.Philip Morris International Inc. - Overview (1/3)
  • 116.Philip Morris International Inc. - Overview (2/3)
  • 117.Philip Morris International Inc. - Overview (3/3)
  • 118.Philip Morris International Inc. - Business segments
  • 119.Philip Morris International Inc. - Key offerings
  • 120.Philip Morris International Inc. - Key customers
  • 121.Philip Morris International Inc. - Segment focus
  • 122.Currency conversion rates for US$
  • 123.Research Methodology
  • 124.Validation techniques employed for market sizing
  • 125.Information sources
  • 126.List of abbreviations